Skip to main content

What West Pharmaceutical Services's Quarter ended Sep 30, 2026 10-Q says: 4 signals

West Pharmaceutical Services filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses cybersecurity incident, divestiture and margin pressure.

Public (WST)Plastics Manufacturing10,000+ employeeswestpharma.comLinkedIn

Get West Pharmaceutical Services' live signals in Claude or ChatGPT, or by API

AskWhat changed at West Pharmaceutical Services this week? Use Autobound signals for westpharma.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
8

Source: Autobound Signal API · 51 signals tracked for West Pharmaceutical Services · updated

10-Q · latest 8

What West Pharmaceutical Services's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 3 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 1 signal

    SEC EDGAR

Earnings calls

West Pharmaceutical Services earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Q3 revenue reaches $874M, growing 11.9% organically with 39.7% marginReported net sales grew 8.7% to $874 million, led by Proprietary Products organic growth of 16.6% and over 4 percentage points of price contribution. Gross margin expanded 310 basis points year-over-year to 39.7%, and operating margin reached 25.3% due to mix shift toward high-value products.
Full-year revenue guidance raised to $3.41B-$3.42B rangeFull-year net sales guidance was increased from $3.345B-$3.38B to $3.41B-$3.42B, projecting full-year organic growth of 11.3% to 11.6% compared to the prior 10% to 11%. Adjusted EPS guidance was also raised to $9.38-$9.48, representing 29% to 30% growth year-over-year.
Michel Lagarde assumes President and Chief Executive Officer roleMichel Lagarde recently joined as President and CEO, bringing over a decade of industry executive experience. His initial priorities center on continuous improvement, factory automation, and elevating customer relationships to a strategic level.
Restructuring West Vantage portfolio toward high-value drug handlingThe company is intentionally rolling off lower-margin legacy programs, including a continuous glucose monitoring contract, to pivot West Vantage toward higher-value drug handling. Management expects this transition to exert a muted effect on segment growth through 2027.
Expanding shop floor automation and operational digitization across facilitiesWest is driving plant-level automation and continuous improvement tools to expand capacity, debottleneck sites, and enhance service levels. The initiative was highlighted at the Eschweiler facility in Germany and is being scaled across global functions.
Working capital drag decreases nine-month free cash flow 5%Nine-month free cash flow dropped 5% year-over-year to $278 million due to growth in customer accounts receivable and higher inventory balances required to support ongoing operations. Working capital pressure was partially offset by moderating capital expenditures.

Signal API · MCP

Track West Pharmaceutical Services with the Signal API

One POST /v1/companies/enrich call with westpharma.com returns West Pharmaceutical Services 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"westpharma.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about West Pharmaceutical Services 10-Q

When did West Pharmaceutical Services file its latest 10-Q?
West Pharmaceutical Services filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Jul 23, 2026.
What did West Pharmaceutical Services disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: West Pharmaceutical sold SmartDose 3.5mL delivery system and facilities to AbbVie on July 1, 2026
What did West Pharmaceutical Services say on its recent earnings calls?
Q3 FY2026: Q3 revenue reaches $874M, growing 11.9% organically with 39.7% margin (dated Oct 29, 2026).
Where can I read West Pharmaceutical Services's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/105770/000010577026000121/wst-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →